Harry Lampiris, MD, Infectious Disease Section, Department of Medicine, San Francisco VA Medical Center Professor of Clinical Medicine, UCSF
Harry Lampiris, MD, reviews the current and future co-formulations available for HIV patients, with an eye towards simplifying antiretroviral treatment regimens. He summarizes research studies on rilpivirine, elvitegravir, cobicistat, dolutegravir and the new tenofovir prodrug, TAF. Evidence from treatment switching studies is reviewed as well.
Video quality will be automatically set based on your connection speed, but can be changed using the "Change quality" toggle, which will appear at the bottom of the player below after you press Play.